Ajay Major, Founder and President of Pager Publications and Assistant Professor of Medicine at the University of Colorado School of Medicine, shared a post on X:
“NAVD real-world outcomes
- 327 patients, med age 37, 24≥60 yrs
- ORR 94% (CR 86%)
- 1-yr PFS 94.5%, OS 99.7%
- irAEs in 29% (9% G3+)
- febrile neutropenia 10%, infections 25% (10% G3+)
RW efficacy mirrors S1826, though notably increased infections (despite GCSF) and irAEs.”
Title: Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers
Authors: Allison M. Bock, Peirong Hao, Yizhe Xu, Efrat Luttwak, Swetha Kambhampati Thiruvengadam, Kanithra Sekaran, Dahlia Sano, John Vaughn, John Sharp, Ajay Major, Vrutti Patel, Gordon Smilnak, Nicole Araujo, Ritwick Mynam, Daniel Reef, Marisa Palmeri, Drew Gerber, Anuja Abhyankar, Grace Baek, Ayo Falade, Madiha Iqbal, Boyu Hu, Praveen Ramakrishnan Geethakumari, Urshila Durani, Mengyang Di, Alex Niu, Hua-Jay J. Cherng, Joanna M. Rhodes, Natalie Grover, Priyanka Pophali, Tatyana Feldman, Krithika Shanmugasundaram, Jakub Svoboda, Timothy Voorhees, Catherine Diefenbach, Yasmin Karimi, Reem Karmali, Alex F. Herrera, Pallawi Torka, Narendranath Epperla
Read the Full Article on HemaSphere
More posts featuring Ajay Major.
